



## NHS MEDICAL POLICY

### Infantile Hemangiomas Procedure 2015-004

#### A. Treatment of infantile hemangiomas may be indicated when ONE of the following is present:

1	The member has Kasabach-Merritt Syndrome. (This is a life-threatening complication occurring with kaposiform hemangioendothelioma (KHE) or tufted angioma. It is characterized by profound thrombocytopenia and consumption coagulopathy.)
2	There is documented functional impairment due to the hemangioma.
3	There is documented compromise of vital structures due to the hemangioma.
4	The hemangioma is symptomatic.

#### B. Treatment of infantile hemangiomas may be done with any of the following techniques, either alone or in combination:

1	Sclerosing therapy
2	Laser therapy
3	Cryosurgery/Cryotherapy
4	Embolization
5	Radiotherapy
6	Surgical excision
7	Intralesional steroids
8	Oral propranolol

## SOURCES

1. UpToDate.com was accessed Jan 8, 2015.
2. Leaute-Labreze C et al. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358 (24): 2649-2651.
3. Nguyen J, Fay A. Pharmacologic therapy for periocular infantile hemangiomas: A review of the literature. Semin Ophthalmol. 2009;24(3):178-184.
4. Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: Report of a consensus conference. Pediatrics. 2013;131(1):128-140.

## CODE REFERENCE (This may not be a comprehensive list of codes to apply to this policy.)

11400-11446, 17106, 17107, 17108, 17110, 17111, 11900, 11901, 77401, 77402, 77403, 77404, 77406

## POLICY HISTORY/REVISION INFORMATION

Date	Action/Description
03/20/2015	Approved in UM committee
12/16/2015	Annual review and approval by UM Committee
12/14/2016	Annual review and approval by UM Committee
12/13/2017	Annual review and approval by UM Committee
12/13/2018	Annual review and approval by UM Committee
12/12/2019	Annual review and approval by UM Committee
12/10/2020	Annual review and approval by UM Committee
12/10/2021	Annual review and approval by UM Committee
12/21/2022	Annual review and approval by UM Committee
12/20/2023	Annual review and approval by UM/QM Committee
12/23/2024	Annual review and approval by UM/QM Committee